Combined carboplatin and paclitaxel therapy improves overall survival in patients with nivolumab‐resistant acral and mucosal melanoma

Maeda, Takuya; Hiura, Azusa; Uehara, Jiro; Toyoshima, Rino; Nakagawa, Tomoe; Yoshino, Koji

doi:10.1111/bjd.20758

Cited by 4 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results were notable for a 12% response rate that was durable in certain cases. 35 In a retrospective study by Maeda et al, 36 the efficacy of carboplatin/paclitaxel treatment for ICI-resistant acral and mucosal BRAF wild-type melanomas was investigated. Patients who received second-line treatment with carboplatin/paclitaxel after progression on first-line treatment with nivolumab, ipilimumab, or nivolumab/ipilimumab combination therapy were evaluated for tumor response rates and survival.…”

Section: Negative Resultsmentioning

confidence: 99%

“…One-year OS was 50% for combined ipilimumab/nivolumab, 12.5% for ipilimumab alone, and 58.3% for carboplatin/paclitaxel. 36 One clinical scenario where chemotherapy may be considered is in patients with immunotherapy toxicity who have BRAF wild-type melanoma. A case study was published that described a patient with stage IV BRAF wild-type cutaneous melanoma who was treated with combination ipilimumab/nivolumab initially.…”

Section: Negative Resultsmentioning

confidence: 99%

“…Patients who received carboplatin/paclitaxel in the second line had superior OS and 3-month PFS rates as compared with patients who received ipilimumab in the second line, but comparable to those who received combination nivolumab/ipilimumab. One-year OS was 50% for combined ipilimumab/nivolumab, 12.5% for ipilimumab alone, and 58.3% for carboplatin/paclitaxel 36 …”

Section: Chemotherapy After Immunotherapymentioning

confidence: 99%

See 2 more Smart Citations

Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?

Fishman,

Buchbinder

2024

Cancer J

View full text Add to dashboard Cite

Immune checkpoint inhibition and targeted therapies have revolutionized the treatment of melanoma. However, chemotherapy and interleukin 2 (IL-2) therapy may still have a role in the later-line treatment of patients who do not have durable responses to other treatments. Chemotherapy can work transiently in patients whose disease has progressed on immune checkpoint inhibitors and for whom there are no appropriate targeted therapy options. High-dose IL-2 therapy can still be effective for a very small number of patients following progression on other therapies. In addition, modified IL-2 agents and IL-2 in combination with tumor-infiltrating lymphocyte therapy may play a role in future treatments for melanoma.

show abstract

Section: Negative Resultsmentioning

confidence: 99%

Section: Negative Resultsmentioning

confidence: 99%

Section: Chemotherapy After Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?

Fishman,

Buchbinder

2024

Cancer J

View full text Add to dashboard Cite

show abstract

“…Since GNAQ mutations are drivers of mitogen-activated protein kinase (MAPK) activation similar to BRAF, new studies have identified selumetinib (a selective MEK inhibitor) as a possible therapy in metastatic uveal melanoma [ 15 ]. Furthermore, carboplatin and paclitaxel, two chemotherapeutic agents that were used in this case, have shown one-year overall survival and three-month progression-free survival in the nivolumab-refractory setting in one trial [ 16 ]. Reasonable responses were also seen in another trial, hence their use in our pregnant patient with PMML [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman

Khatri¹,

Kashfi²,

Griffin³

2023

Cureus

View full text Add to dashboard Cite

Mucosal melanoma represents a small proportion of all melanoma cases and is associated with a worse prognosis. Primary malignant melanoma of the lip (PMML) is far less common, and only a few cases have been reported since 1997, most commonly in China, Japan, Uganda, and India. Most of these cases have been associated with the gene C-KIT. As a result, treatment guidelines surrounding mucosal melanoma are unclear, especially in complicated populations such as pregnant women. Mutations in theGNAQ and GNA11 genes have been found to be associated with uveal melanoma, while they are rarely associated with mucosal melanoma. We present the case of a 23-year-old pregnant woman who was found to have likely primary malignant melanoma of the lip that metastasized to the left jaw, neck, breast, lungs, and ovaries and was found to be positive for both the BRAF-MLL3 and GNA11 mutation.

show abstract

“…While chemotherapy is not the first-line treatment for advanced melanoma, it is often used after immunotherapy/targeted therapy failure in patients, and chemoresistance is one of the barriers to its effectiveness (American Cancer Society, 2022b; Goldinger et al, 2022;Kalal et al, 2017). PTX is part of the chemotherapy portfolio used in advanced melanoma (Samoylenko et al, 2016;Maeda et al, 2022), and its effectiveness can be dampened by various drug resistance mechanisms (Castro et al, 2022). The ability of the CM from the rHDL-DPM NPs-, and rHDL-DPM-DMXAA NPs-treated macrophages to modulate the proliferation and to improve the sensitivity of the B16-F10 cells to PTX suggest that the rHDL-DPM NPs could be a valuable tool in mitigating chemoresistance to PTX in B16-F10 tumor-bearing mice.…”

Section: Discussionmentioning

confidence: 99%

Mannose-functionalization of reconstituted high-density lipoprotein nanoparticles improves payload delivery and enhances M2-to-M1 phenotype reprogramming of RAW 264.7 macrophages polarized by B16-F10 melanoma cells

Dossou,

Mantsch,

Sabnis

et al. 2023

Front. Drug Deliv.

View full text Add to dashboard Cite

The targeting and conversion of the immunosuppressive (M2) tumor-associated macrophages (TAMs) to an immunostimulatory (M1) phenotype can induce tumor regression in advanced melanoma. We have previously characterized and reported the ability of reconstituted high-density lipoprotein nanoparticles (rHDL NPs) functionalized with DSPE-PEG-mannose (DPM) to deliver payload to macrophages. Herein, we investigate the modulation of macrophage phenotype and payload delivery mechanisms of the rHDL-DPM NPs in RAW 264.7 murine macrophages exposed to the conditioned medium (CM) from murine B16-F10 melanoma cells. The rHDL-DPM NPs loaded with the Stimulator of Interferon genes agonist, DMXAA, reduced protein levels of M2 markers. Through the mannose moiety, the rHDL-DPM-DMXAA NPs enhanced the production of interferon β and CXCL10 compared to the free DMXAA in the B16-F10 CM-educated RAW 264.7 macrophages. Compared to their non-mannosylated counterpart, the rHDL-DPM NPs delivered their payload more efficiently to the B16-F10 CM-educated RAW 264.7 macrophages. Mechanistically, both the scavenger receptor type B class 1 (SR-B1) and the mannose receptor (CD206) facilitated payload delivery to the macrophages via endocytic and non-endocytic mechanisms. Finally, the CM from rHDL-DPM-DMXAA NPs -treated macrophages enhanced paclitaxel (paclitaxel)-mediated cytotoxicity in B16-F10 cells. Together, these in vitro findings demonstrate the potential of the mannose-functionalized rHDL NPs in improving the targeting of M2-like TAMs and treatment outcomes when combined with immunotherapy or PTX in B16-F10 melanoma in vivo models.

show abstract

Combined carboplatin and paclitaxel therapy improves overall survival in patients with nivolumab‐resistant acral and mucosal melanoma

Abstract: F, Kirtschig G et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 2017; 389:1630-8.

Cited by 4 publications

References 8 publications

Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?

Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?

Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman

Mannose-functionalization of reconstituted high-density lipoprotein nanoparticles improves payload delivery and enhances M2-to-M1 phenotype reprogramming of RAW 264.7 macrophages polarized by B16-F10 melanoma cells

Contact Info

Product

Resources

About